Is DIM.PA undervalued or overvalued?
As of 2025-03-23, the Intrinsic Value of Sartorius Stedim Biotech SA (DIM.PA) is 134.56 EUR. This DIM.PA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 194.80 EUR, the upside of Sartorius Stedim Biotech SA is -30.90%. This means that DIM.PA is overvalued by 30.90%.
The range of the Intrinsic Value is 66.99 - 711.14 EUR
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 66.99 - 711.14 | 134.56 | -30.9% |
| DCF (Growth 10y) | 116.84 - 1,115.85 | 222.11 | 14.0% |
| DCF (EBITDA 5y) | 110.72 - 159.29 | 139.47 | -28.4% |
| DCF (EBITDA 10y) | 162.82 - 261.08 | 214.49 | 10.1% |
| Fair Value | 25.11 - 25.11 | 25.11 | -87.11% |
| P/E | 46.48 - 70.11 | 56.16 | -71.2% |
| EV/EBITDA | 62.52 - 110.96 | 87.02 | -55.3% |
| EPV | 20.22 - 47.50 | 33.86 | -82.6% |
| DDM - Stable | 19.18 - 168.80 | 93.99 | -51.8% |
| DDM - Multi | 65.88 - 451.01 | 115.00 | -41.0% |
| Market Cap (mil) | 18,959.88 |
| Beta | 1.06 |
| Outstanding shares (mil) | 97.33 |
| Enterprise Value (mil) | 21,150.48 |
| Market risk premium | 5.82% |
| Cost of Equity | 7.26% |
| Cost of Debt | 5.57% |
| WACC | 6.87% |